drugset / Trial / NCT02442778
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National Institute on Aging (NIA)-Alzheimer's Association (AA) workgroups.
Timeline
- Start
- 2015-11-11
- Primary completion
- 2019-08-14
- Completion
- 2019-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deudextromethorphan | Unknown | 18 mg | Oral |
| Subject | Deudextromethorphan | Unknown | 28 mg | Oral |
| Subject | Deudextromethorphan | Unknown | 42.63 mg | Oral |
| Subject | Quinidine | Small molecule | 4.9 mg | Oral |
Indications
No indication recorded.